Naturland Holding ZrtBUD:NATURLAND 61 Return-on-Tangible-Asset is 31.10% as of Jun. 2025, which is 2% above its 10-year median of 30.54. GuruFocus rates BUD:NATURLAND with a GF Score™ of 61/100 and a GF Value™ of Ft2,884.19 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Naturland Holding Zrt ranks better than 98.41% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Naturland Holding Zrt's annualizedNet Income for the quarter that ended in Jun. 2025 was Ft1,418 Mil. Naturland Holding Zrt's average total tangible assets for the quarter that ended in Jun. 2025 was Ft4,559 Mil. Therefore, Naturland Holding Zrt's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2025 was 31.10%.
The historical rank and industry rank for Naturland Holding Zrt's Return-on-Tangible-Asset or its related term are showing as below:
BUD:NATURLAND'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 25.1 Med: 30.54 Max: 64.33
Current: 33.22
During the past 5 years, Naturland Holding Zrt's highest Return-on-Tangible-Asset was 64.33%. The lowest was 25.10%. And the median was 30.54%.
BUD:NATURLAND's Return-on-Tangible-Asset is ranked better than 98.41% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs BUD:NATURLAND: 33.22
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Naturland Holding Zrt Return-on-Tangible-Asset Related Terms
Naturland Holding Zrt Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Naturland Holding Zrt's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NATURLAND vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2025) net income data.
What does a Return-on-Tangible-Asset of 31.10% mean?
Naturland Holding Zrt (BUD:NATURLAND) has a Return-on-Tangible-Asset of 31.10% as of Jun. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Naturland Holding Zrt and its competitors. This is near median its historical median of 30.54. Over the past decade, Naturland Holding Zrt's Return-on-Tangible-Asset has ranged from 25.10 to 64.33. According to the industry distribution chart, Naturland Holding Zrt ranks #16 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is Naturland Holding Zrt's Return-on-Tangible-Asset too high?
Naturland Holding Zrt's current Return-on-Tangible-Asset of 31.10% is near median its 10-year median of 30.54. Over the past 10 years, this metric has ranged from a low of 25.10 to a high of 64.33. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Naturland Holding Zrt's value of 31.10% is 887.3% above this industry median. Based on the distribution chart, Naturland Holding Zrt ranks #16 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Naturland Holding Zrt ranks #16 out of 1005 companies for Return-on-Tangible-Asset. This places Naturland Holding Zrt in the top 2% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Naturland Holding Zrt's value of 31.10% is 887.3% above this benchmark. Historically, Naturland Holding Zrt's own Return-on-Tangible-Asset has ranged from 25.10 to 64.33 over the past decade. While the company's 10-year median is 30.54 vs. the industry median of 3.15, Naturland Holding Zrt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current Return-on-Tangible-Asset of 31.10% is 887.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Naturland Holding Zrt and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current Return-on-Tangible-Asset is 31.10%, which is near median its own 10-year median of 30.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,884.19, compared to a current price of Ft2,800.00 — trading 2.9% below its estimated fair value. The current Return-on-Tangible-Asset is 31.10%, which is near median its 10-year median of 30.54 and 887.3% above the Drug Manufacturers industry median of 3.15. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current Return-on-Tangible-Asset is 31.10% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,800.00 is trading 2.9% below its estimated GF Value™ of Ft2,884.19.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
Return-on-Tangible-Asset: 31.10% (near median its 10-year median of 30.54)
GF Value™: Ft2,884.19 vs. price of Ft2,800.00 (2.9% below fair value)
Industry Position: 887.3% above the Drug Manufacturers median (#16 of 1005)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
